Chronic renal disease
Conditions
Interventions
None listed
Sponsors
RESTART Study group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Outpatients who had been treated with more than 4h dialysis three times a week. 2) Patients who had been treated more than 3 months with polysulfone type dialyzers excluding NV, (their dialysis vintages are more than 3 months). 3) Patients who had been more than 20 years old. 4) Patients to whom erythropoiesis stimulating agent had been prescribed
Exclusion criteria
Exclusion criteria: For 3 months before the beginning of observation and during observation period, patients who had fulfilled conditions below were excluded. 1) Patients who had been treated with other renal insufficiency therapies, continuous ambulatory peritoneal dialysis and hemodiafiltration, excluding hemodialysis. 2) Patients to whom Epoetin Beta Pegol (CERA) had been prescribed. 3) Patients to whom blood transfusion had been conducted. 4) Patients who had been hospitalized for more than 2 weeks. 5) Patients who had become pregnant or given birth. 6) Patients who had hematologic diseases excluding renal anemia. 7) Patients who had been treated for a malignant tumor. 8) Patients who is judged as the inadequate subject of this study by the doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Responsibility for erythropoiesis stimulating agent 6 or 12 months after the beginning of observation. | — |
Countries
Japan
Contacts
Public ContactTakatoshi Kakuta
Tokai University Hachioji Hospital ivision of Nephrology, Endocrinology and Metabolism
Outcome results
None listed